CRP and hepatocellular carcinoma: Given the increasing appreciation of the TME as a critical regulator of tumor immunity and immunotherapy (43, 44), the serum CRP level might serve as a simple indicator of the immune status in the tumor site and thus has a potential application for treatment strategies targeting the immunosuppressive TME for patients with HCC.